
Kyverna has completed its BLA submission to the FDA for miv-cel, its investigational therapy for stiff person syndrome, and requested Priority Review. The FDA will now decide whether to accept it. Miv-cel isn’t FDA-approved.


Kyverna has completed its BLA submission to the FDA for miv-cel, its investigational therapy for stiff person syndrome, and requested Priority Review. The FDA will now decide whether to accept it. Miv-cel isn’t FDA-approved.

➡️ Take a look at highlights from #ACR26! 💜 Our team shared important #lupus research findings and connected with researchers, healthcare professionals and advocates to discuss the future of lupus care. Explore our recap blog: buff.ly/WVOwAIl

Mckenna Bowes, a medical student and #lupuswarrior, spoke at #ACR26 opening session and presented a poster looking for differences among children with lupus who had seizures at baseline and those that didn’t using the @carrainc registry. Love seeing research on #npsle. #LADAorg

AI, health inequalities and EU policy were on the agenda at EULAR PARE Conference in Brussels. Proud to take part, with @Jeanette_Lupus, Chair of the Lupus Europe Board, presenting #LupusGPT & the role of patient organisations in shaping responsible AI. Thanks @eular_org PARE!

CAR-T therapy for autoimmune diseases: Are we ready? Dr. George Tsokos, Chief of Rheumatology at BIDMC, presented the “Not Yet” perspective at #ACR26, highlighting the promise, pitfalls, and risks of premature enthusiasm for CAR-T therapy in autoimmunity.

Thanks to our friends at @IAFaccess for providing this patient-reviewed product. I’ve already reached out for info to purchase the purple 💜 for home infusion. #lupus @LADAOrg
Huge thanks to Spongies for being such an amazing partner! 🙌 Our Champion Nya tested their products, and she loved them. We’re so excited to keep highlighting infusion-related products that genuinely support our community.

Are you at the #ACR26? Come and visit our poster on predictors of flares after achieving drug-free remission in the #SLICC cohort by @bhrasco @GEAS_Peru

Treasury's proposed COINS Act rule would cut U.S. companies off from biotech research abroad, and from breakthroughs people with lupus are counting on. National security matters, but medical R&D isn't a threat. It's hope. Protect Americans’ access to cures.

Soooo glad you met & got to learn more about correlation of step count & CRP levels. Congrats @SarahSisbot #patientinsights @LADAOrg @AChVoice
At #ACR26 with @LADAOrg and got to meet @SarahSisbot and learn about how she correlated her steps taken with her CRP levels. Wonderful to connect with other patient advocates and hear their stories represented. #LADAorg

About 12% of Americans have T2 #diabetes, increasing the risk of developing #cancer and cardiovascular disease. US patients have earlier access to life-extending treatments than in other countries. Yet #MFN threatens that access. bit.ly/4k3BgGP #NationalDiabetesMonth


Yay! Cheering loudly for this team, part of #BostonRheumRoyalty 💁🏻♀️💜 @LupusNE
💙 UMass Rheumatology representing at #ACR26! Great to see our team together, sharing research, exchanging ideas, and connecting with colleagues from across the rheumatology community! Proud of our amazing team! 👏 #UMassRheum #UMassLupus

A lab test that stresses a patient’s own immune cells may predict who will respond to TNF inhibitors for psoriatic arthritis and IBD. Early data from @NYULangone at #ACR26. ⤵️

🚨 “AMETHYST represents the first #cutaneous #lupus trial designed in this way,” Dr. @JosephMerolaMD @ACRheum.

Same lupus. Different immune biology. Beyond anti-dsDNA and complement—#ACR26 insights: • Tph cells and atypical B cells expand in SLE, linking T–B cell activation with flares. • Blood profiling identifies 3 lupus nephritis groups: immunologically inactive, IFN-high and cytotoxic T-cell dominant—with differing renal pathology and treatment responses. • IFN signatures/SIGLEC-1 can track pathway suppression after anifrolumab. The next frontier: matching treatment to immune biology. Promising; biomarker-guided prescribing still needs validation. Credit: Dr Deepak Rao #ACRAmbassador #Lupus #LupusNephritis #PrecisionMedicine

Cheering extra loud for members of #BostonRheumRoyalty - congrats! #ACR26 💜
Happening now at #ACR26! 🔬 Our BIDMC Rheumatology fellow Dr. Ryan Payne is presenting his research on treatment patterns, hematologic response, and glucocorticoid exposure in SLE-associated hemolytic anemia! 📍 Poster 0250 | Hall WB1&2 Stop by and say hello! 👏